Duration of trastuzumab for HER2-positive breast cancer
Mené dans 156 centres français sur 1 691 patientes atteintes d'un cancer du sein HER2+, cet essai de phase III promu par l'Institut national du cancer (PHARE) compare, du point de vue de la survie sans maladie, deux durées d'administration (6 et 12 mois) du trastuzumab en traitement adjuvant (durée médiane de suivi : 42,5 mois)
Several large randomised trials completed in the mid-2000s produced overwhelming evidence that the anti-HER2 monoclonal antibody trastuzumab, administered either concomitantly or sequentially with adjuvant chemotherapy for 12 months, increases the cure rate for women with HER2-positive operable breast cancer. One surprising aspect of this success story is that the choice of 12-month treatment duration was mostly as a result of a best guess, rather than on the basis of pre-existing evidence...
The Lancet Oncology , commentaire, 2012